Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity
- PMID: 18781377
- DOI: 10.1007/s11095-008-9724-y
Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity
Abstract
Purpose: To design and evaluate liposomal constructs capable of inducing a potent systemic and airway humoral response to Pseudomonas aeruginosa
Methods: Liposomes contained a peptide derived from P. aeruginosa pilin protein as B epitope, a peptide derived from Influenza hemagglutinin protein as Th epitope, the TLR agonist Pam3CAG or Pam2CAG as adjuvant, and a mannosylated lipid as dendritic cell targeting agent. These constructions were administered to mice intraperitoneally (i.p.) or intranasally (i.n.). Their immunogenicity was evaluated by measuring B epitope-specific immunoglobulins in the serum and the airways by ELISA.
Results: The B epitope, in its native form or after substitution of a cysteine by a serine, induced high systemic IgG titers when formulated in the presence of Pam3CAG or Pam2CAG and administered i.p.. No IgA response was observed in the airways upon injection of candidate vaccines by i.p. route, whatever the B epitope or the adjuvant. However, i.n. vaccination resulted in a significant local production of IgA. Finally, the production of IgG was more rapid when mannose was incorporated.
Conclusions: All liposomal candidate vaccines tested induced the production of IgG and/or IgA directed against an immunogenic peptide from P. aeruginosa. Liposomal constructs could be attractive in the vaccination against P. aeruginosa.
Similar articles
-
Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.Appl Microbiol Biotechnol. 2015 Jan;99(2):667-80. doi: 10.1007/s00253-014-6147-z. Epub 2014 Nov 11. Appl Microbiol Biotechnol. 2015. PMID: 25381907
-
Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.Microbiol Immunol. 2015 Sep;59(9):533-44. doi: 10.1111/1348-0421.12291. Microbiol Immunol. 2015. PMID: 26249788
-
Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.Respir Res. 2007 Aug 5;8(1):57. doi: 10.1186/1465-9921-8-57. Respir Res. 2007. PMID: 17683588 Free PMC article. Clinical Trial.
-
PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response.Vaccine. 2025 Jul 11;60:127306. doi: 10.1016/j.vaccine.2025.127306. Epub 2025 May 26. Vaccine. 2025. PMID: 40424705
-
Recent developments for Pseudomonas vaccines.Hum Vaccin. 2011 Oct;7(10):999-1011. doi: 10.4161/hv.7.10.16369. Epub 2011 Oct 1. Hum Vaccin. 2011. PMID: 21941090 Free PMC article. Review.
Cited by
-
From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.Bioconjug Chem. 2013 Jan 16;24(1):85-96. doi: 10.1021/bc300498d. Epub 2013 Jan 7. Bioconjug Chem. 2013. PMID: 23186007 Free PMC article.
-
Mucosal Vaccine Development Based on Liposome Technology.J Immunol Res. 2016;2016:5482087. doi: 10.1155/2016/5482087. Epub 2016 Dec 29. J Immunol Res. 2016. PMID: 28127567 Free PMC article. Review.
-
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators.Pharmaceutics. 2016 Mar 10;8(1):7. doi: 10.3390/pharmaceutics8010007. Pharmaceutics. 2016. PMID: 26978390 Free PMC article. Review.
-
Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations.Int J Mol Sci. 2025 Feb 25;26(5):2012. doi: 10.3390/ijms26052012. Int J Mol Sci. 2025. PMID: 40076637 Free PMC article. Review.
-
Licensed liposomal vaccines and adjuvants in the antigen delivery system.BioTechnologia (Pozn). 2022 Dec 24;103(4):409-423. doi: 10.5114/bta.2022.120709. eCollection 2022. BioTechnologia (Pozn). 2022. PMID: 36685697 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous